{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:49:03Z","timestamp":1794584943645,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ygyno.2024.05.026","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T14:40:51Z","timestamp":1717166451000},"page":"235-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants"],"prefix":"10.1016","volume":"187","author":[{"given":"Stephanie","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"Godley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ygyno.2024.05.026_bb0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.026_bb0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/2159-8290.CD-23-1091","article-title":"Insights into the molecular mechanisms of genetic predisposition to hematopoietic malignancies: the importance of gene-environment interactions","volume":"14","author":"Cobaleda","year":"2024","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.026_bb0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0020","first-page":"351","article-title":"Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies","volume":"109","author":"Stubbins","year":"2023","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.ygyno.2024.05.026_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246385","article-title":"PARP inhibitors and myeloid neoplasms: a double-edged sword","volume":"13","author":"Csizmar","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.026_bb0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020","volume":"18","author":"Daly","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0035","first-page":"21","article-title":"Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population","volume":"13","author":"da Costa","year":"2020","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ygyno.2024.05.026_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102522","article-title":"Germline TP53 pathogenic variants and breast cancer: a narrative review","volume":"114","author":"Blondeaux","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12885-017-3940-y","article-title":"Variants of cancer susceptibility genes in Korean BRCA1\/2 mutation-negative patients with high risk for hereditary breast cancer","volume":"18","author":"Park","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0050","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12935-021-01976-y","article-title":"Mismatch repair-deficient hormone receptor-positive breast cancers: biology and pathological characterization","volume":"21","author":"Sajjadi","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/ijms23010348","article-title":"Homologous recombination deficiencies and hereditary tumors","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ygyno.2024.05.026_bb0060","doi-asserted-by":"crossref","first-page":"e1526","DOI":"10.1002\/onco.13829","article-title":"Homologous recombination deficiency: cancer predispositions and treatment implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"issue":"22","key":"10.1016\/j.ygyno.2024.05.026_bb0065","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond","volume":"1","author":"Hansford","year":"2015","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3665-z","article-title":"Breast cancer risk and clinical implications for germline PTEN mutation carriers","volume":"165","author":"Ngeow","year":"2017","journal-title":"Breat Cancer Res. Treat."},{"issue":"13","key":"10.1016\/j.ygyno.2024.05.026_bb0080","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.026_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2023.11.019","article-title":"Pathogenic germline variants in non-BRCA1\/2 homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival","volume":"180","author":"Kahn","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.026_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.05.026_bb0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/em.22505","article-title":"A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies","volume":"63","author":"Shao","year":"2022","journal-title":"Environ. Mol. Mutagen."},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.026_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.026_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2018.10.013","article-title":"The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: understanding the baseline incidence","volume":"151","author":"Sella","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.026_bb0110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.026_bb0115","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.2147\/OTT.S101333","article-title":"Therapy-related myeloid neoplasms: clinical perspectives","volume":"11","author":"Fianchi","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"9","key":"10.1016\/j.ygyno.2024.05.026_bb0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood.2021010764","article-title":"What\u2019s new in the pathogenesis and treatment of therapy-related myeloid neoplasms","volume":"138","author":"Voso","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0125","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2023.064","article-title":"Therapy-related myeloid neoplasms: predisposition and clonal evolution: t-AML predisposition","volume":"15","author":"Fabiani","year":"2023","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ygyno.2024.05.026_bb0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","article-title":"Therapy-related myeloid neoplasms","volume":"23","author":"Leone","year":"2011","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.026_bb0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-009-0376-3","article-title":"Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study","volume":"118","author":"Martin","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.ygyno.2024.05.026_bb0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.026_bb0145","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.05.026_bb0150","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S2352-3026(20)30375-6","article-title":"PARP inhibitors\u2014understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia","volume":"8","author":"Tinker","year":"2021","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.026_bb0155","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ijgc-2022-004190","article-title":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2024.05.026_bb0160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.026_bb0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10689-023-00331-6","article-title":"Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1\/BRCA2 germline pathogenic variants. A single center experience and review of the literature","volume":"22","author":"Hu-Heimgartner","year":"2023","journal-title":"Fam. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2024.05.026_bb0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11899-022-00676-2","article-title":"Role of germline predisposition to therapy-related myeloid neoplasms","volume":"17","author":"Baranwal","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.026_bb0175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.026_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc970","article-title":"The Fanconi anaemia\/BRCA pathway","volume":"3","author":"D\u2019Andrea","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.ygyno.2024.05.026_bb0185","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1093\/hmg\/ddv251","article-title":"FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor","volume":"24","author":"Peterlongo","year":"2015","journal-title":"Hum. Mol. Genet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582400249X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582400249X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:42:38Z","timestamp":1745329358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582400249X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"alternative-id":["S009082582400249X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}